Pharmafile Logo

Prosonix

Secondary effects of COVID-19 on the healthcare system and patients

We are getting to the point where we need to start considering the long-term effects on the healthcare system when making decisions.

Impetus Digital

If our patients are diverse, why are clinical trials so white?

Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue...

Blue Latitude Health

Impetus Digital Fireside Chat with MindSet

Ryan Zarychanski, Paul Komenda, and Marshall Pitz from MindSet, discuss a whole range of thought-provoking topics, including the barriers to and benefits of clinical data integration for the healthcare system, clinical trials, providers,...

Impetus Digital

We are COUCH Health

Making health human means that everything we do puts people first. __Pharmaceutical, biotech and life science companies turn to us to help them build strong connections with, and improve outcomes...

COUCH Health

https://vimeo.com/422463636

Demand Diversity Podcast

The unacceptable lack of diversity among clinical research participants would suggest that we are.As we begin our campaign to demand diversity in the clinical research space, we invite you to...

COUCH Health

Impetus Digital Fireside Chat with Craig Lipset from Clinical Innovation Partners

Craig Lipset, Founder and Advisor at Clinical Innovation Partners and former Head of Clinical Innovation and Venture Partner at Pfizer, discusses everything from his personal health journey to his professional accomplishments,...

Impetus Digital

Impetus Digital Fireside Chat with Esther Schorr from Patient Power LLC

Esther Schorr, Co-founder and Chief Operating Officer of Patient Power, discusses her non-linear journey to patient education and Patient Power's mission to empower patients and their loved ones to take control...

Impetus Digital

Assessing the value of interim analyses in clinical trials

Why its important and when its needed

Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603

Onyx Health

- PMLiVE

Integrating electronic health records into clinical trials

How organisations are working to realise the research potential of EHRs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links